The MicroRNAs in the pathogenesis of metabolic memory

Endocrinology (United States)

Volumn 156, Issue 9, 2015, Pages 3157-3168

  Zhong, Xueyu ^a   Liao, Yunfei ^a   Chen, Lulu ^a   Liu, Geng ^a   Feng, Yong ^a   Zeng, Tianshu ^a   Zhang, Jingjing ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Yichang Central Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 6; MICRORNA; MICRORNA 125B; MICRORNA 146A 5P; MICRORNA 29A 3P; MONOCYTE CHEMOTACTIC PROTEIN 1; SYNAPSIN II; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, RAT;

AORTA ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; METABOLIC DISORDER; METABOLIC MEMORY; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL MODEL; AORTA; CELL CULTURE; DIABETIC ANGIOPATHIES; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; MALE; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZATION; RAT; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALS; AORTA; CELLS, CULTURED; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYPERGLYCEMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICRORNAS; MODELS, ANIMAL; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 84942764886     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1063     Document Type: Article

References (33)

1. Nathan DM, Cleary PA, Backlund J.Y., et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353:2643-2653.
2. White NH, Sun W, Cleary P.A., et al; DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010; 59:1244-1253.
3. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015; 58: 443-455.
4. Kong YW, Cannell IG, de Moor CH, et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA. 2008; 105:8866-8871.
5. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005; 4:1179-1184.
6. McClelland AD, Kantharidis P. MicroRNA in the development of diabetic complications. Clin Sci (Lond). 2014; 126:95-110.
7. Feng B, Chen S, McArthur K., et al. MiR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes. 2011; 60:2975-2984.
8. Zhong Q, Kowluru RA Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes. 2011; 60:1304-1313.
9. Mombouli JV, Nakashima M, Hamra M., Vanhoutte PM. Endothelium-dependent relaxation and hyperpolarization evoked by bradykinin in canine coronary arteries: enhancement by exercise-training. Br J Pharmacol. 1996; 117:413-418.
10. Brasacchio D, Okabe J, Tikellis C., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009; 58:1229-1236.
11. Kim SW, Ramasamy K, Bouamar H., Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-ΚB pathway by targeting the tumor necrosis factor Α-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA. 2012; 109: 7865-7870.
12. Hymowitz SG, Wertz IE A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer. 2010; 10:332-341.
13. Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996; 271:1128-1131.
14. Cao Z, Xiong J, Takeuchi M., Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature. 1996; 383:443-446.
15. Klose RJ, Bird AP Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006; 31:89-97.
16. Takizawa F, Mizutani S, Ogawa Y., Sawada N. Glucose-indepen-dentpersistence of PAI-1 gene expression and H3K4 tri-methylation in type 1 diabetic mouse endothelium: implication in metabolic memory. Biochem Biophys Res Commun. 2013; 433:66-72.
17. El-Osta A., Brasacchio D, Yao D., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008; 205:2409-2417.
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N EnglJ Med. 2000; 342:381-389.
19. Bird A. Perceptions of epigenetics. Nature. 2007; 447:396-398.
20. Nesca V, Guay C, Jacovetti C., et al. Identification of particular groups of microRNAs that positively or negatively impact on β cell function in obese models of type 2 diabetes. Diabetologia. 2013; 56:2203-2212.
21. Lovis P, Roggli E, Laybutt D.R., et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic β-cell dysfunction. Diabetes. 2008; 57:2728-2736.
22. Zampetaki A, Kiechl S, Drozdov I., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010; 107:810-817.
23. Kong L, Zhu J, Han W., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011; 48:61-69.
24. Vickers KC, Rye KA, Tabet F. MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond). 2014; 126:183-194.
25. Villeneuve LM, Kato M, Reddy M.A., Wang M., Lanting L, Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes. 2010; 59:2904-3015.
26. Wang HJ, Huang YL, Shih Y.Y., Wu HY, Peng CT, Lo WY. MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression. Mediators Inflamm. 2014; 2014:379537.
27. Rask-Madsen C., King GL Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007; 3:46-56.
28. Thurberg BL, Collins T. The nuclear factor-κ B/inhibitor of κ B autoregulatory system and atherosclerosis. Curr Opin Lipidol. 1998; 9:387-396.
29. Glass CK, Witztum JL Atherosclerosis. the road ahead. Cell. 2001; 104:503-516.
30. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-ΚB/ Rel transcription factors defines functional specificities. EMBO J. 2003; 22:5530-5539.
31. Taganov KD, Boldin MP, Chang K.J., Baltimore D. NF-ΚB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006; 103:12481-12486.
32. Bhaumik D, Scott GK, Schokrpur S, Patil C.K., Campisi J., Benz CC. Expression of microRNA-146 suppresses NF-ΚB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008; 27:5643-5647.
33. Schmitt MJ, Margue C, Behrmann I., Kreis S. MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med. 2013; 13:572-585.